1,558 reports of this reaction
2.2% of all FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE reports
#9 most reported adverse reaction
ASTHMA is the #9 most commonly reported adverse reaction for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, manufactured by GlaxoSmithKline LLC. There are 1,558 FDA adverse event reports linking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE to ASTHMA. This represents approximately 2.2% of all 70,190 adverse event reports for this drug.
Patients taking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE who experience asthma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHMA is a less commonly reported adverse event for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, but still significant enough to appear in the safety profile.
In addition to asthma, the following adverse reactions have been reported for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE:
The following drugs have also been linked to asthma in FDA adverse event reports:
ASTHMA has been reported as an adverse event in 1,558 FDA reports for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHMA accounts for approximately 2.2% of all adverse event reports for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, making it a notable side effect.
If you experience asthma while taking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.